27 research outputs found
Recommendations for surveillance of pulmonary dysfunction among childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
\ua9 2024. Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines are discordant. Therefore, the International Late Effects of Childhood Cancer Guideline Harmonization Group established and convened a panel of 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding risk factors for pulmonary dysfunction, types of pulmonary function testing, and timings of surveillance, then we formulated our recommendations. We recommend that CAYA cancer survivors and healthcare providers are aware of reduced pulmonary function risks and pay vigilant attention to potential symptoms of pulmonary dysfunction, especially among survivors treated with allogeneic haematopoietic stem cell transplantation, thoracic radiotherapy, and thoracic surgery. Based on existing limited evidence and current lack of interventions, our panel recommends pulmonary function testing only for symptomatic survivors. Since scarce existing evidence informs our recommendation, we highlight the need for prospective collaborative studies to address pulmonary function knowledge gaps among CAYA cancer survivors
Risk Factors and the Prevention of Weight Gain During Induction Chemotherapy in Children With Acute Lymphoblastic Leukemia.
In a recent issue of the Journal of Pediatric Hematology/Oncology, Seki and colleagues reported on risk factors for weight gain during induction chemotherapy in 96 childhood acute lymphoblastic leukemia (ALL) patients. In a retrospective study of medical records, they found that non–high-risk treatment for childhood ALL and treatment start date before daily weight measurement were risk factors for weight gain during induction therapy. They concluded that daily body weight measurements might prevent weight gain during induction therapy and can result in maintaining a healthy weight after aLL treatment.
We agree that early weight management should be emphasized, but question the study’s conclusions because of its methodological weaknesses. The retrospective design could have introduced surveillance bias and confounding. During the second half of the study period (after 2005), more focus was put on weight management as daily body weight measurements were initiated in an attempt to control weight. Patients who experienced weight gain in the second half of the study (after 2005) may have been more closely monitored than patients in the first half of the study (before 2005). The closer surveillance could potentially have led to difference in management, for example, diet control and water retention. Reverse causation may have occurred: overall differences in weight management, not the daily weight measurements, caused a weight reduction. More details on how weight gain found during induction was handled in the 2 periods would have helped the reader interpret this study.2 In the future, an intervention study with weight monitoring procedures in addition to normal clinical practice of daily weight measurements would assist gaining insight into good management of weight reduction
Oral or transdermal opioids for osteoarthritis of the knee or hip
BACKGROUND: Osteoarthritis is the most common form of joint disease and the
leading cause of pain and physical disability in older people. Opioids may be a
viable treatment option if people have severe pain or if other analgesics are
contraindicated. However, the evidence about their effectiveness and safety is
contradictory. This is an update of a Cochrane review first published in 2009.
OBJECTIVES: To determine the effects on pain, function, safety, and addiction of
oral or transdermal opioids compared with placebo or no intervention in people
with knee or hip osteoarthritis.
SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE and CINAHL (up to 28 July 2008, with an update
performed on 15 August 2012), checked conference proceedings, reference lists,
and contacted authors.
SELECTION CRITERIA: We included randomised or quasi-randomised controlled trials
that compared oral or transdermal opioids with placebo or no treatment in people
with knee or hip osteoarthritis. We excluded studies of tramadol. We applied no
language restrictions.
DATA COLLECTION AND ANALYSIS: We extracted data in duplicate. We calculated
standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain
and function, and risk ratios for safety outcomes. We combined trials using an
inverse-variance random-effects meta-analysis.
MAIN RESULTS: We identified 12 additional trials and included 22 trials with 8275
participants in this update. Oral oxycodone was studied in 10 trials, transdermal
buprenorphine and oral tapentadol in four, oral codeine in three, oral morphine
and oral oxymorphone in two, and transdermal fentanyl and oral hydromorphone in
one trial each. All trials were described as double-blind, but the risk of bias
for other domains was unclear in several trials due to incomplete reporting.
Opioids were more beneficial in pain reduction than control interventions (SMD
-0.28, 95% CI -0.35 to -0.20), which corresponds to a difference in pain scores
of 0.7 cm on a 10-cm visual analogue scale (VAS) between opioids and placebo.
This corresponds to a difference in improvement of 12% (95% CI 9% to 15%) between
opioids (41% mean improvement from baseline) and placebo (29% mean improvement
from baseline), which translates into a number needed to treat (NNTB) to cause
one additional treatment response on pain of 10 (95% CI 8 to 14). Improvement of
function was larger in opioid-treated participants compared with control groups
(SMD -0.26, 95% CI -0.35 to -0.17), which corresponds to a difference in function
scores of 0.6 units between opioids and placebo on a standardised Western Ontario
and McMaster Universities Arthritis Index (WOMAC) disability scale ranging from 0
to 10. This corresponds to a difference in improvement of 11% (95% CI 7% to 14%)
between opioids (32% mean improvement from baseline) and placebo (21% mean
improvement from baseline), which translates into an NNTB to cause one additional
treatment response on function of 11 (95% CI 7 to 14). We did not find
substantial differences in effects according to type of opioid, analgesic
potency, route of administration, daily dose, methodological quality of trials,
and type of funding. Trials with treatment durations of four weeks or less showed
larger pain relief than trials with longer treatment duration (P value for
interaction = 0.001) and there was evidence for funnel plot asymmetry (P value =
0.054 for pain and P value = 0.011 for function). Adverse events were more
frequent in participants receiving opioids compared with control. The pooled risk
ratio was 1.49 (95% CI 1.35 to 1.63) for any adverse event (9 trials; 22% of
participants in opioid and 15% of participants in control treatment experienced
side effects), 3.76 (95% CI 2.93 to 4.82) for drop-outs due to adverse events (19
trials; 6.4% of participants in opioid and 1.7% of participants in control
treatment dropped out due to adverse events), and 3.35 (95% CI 0.83 to 13.56) for
serious adverse events (2 trials; 1.3% of participants in opioid and 0.4% of
participants in control treatment experienced serious adverse events). Withdrawal
symptoms occurred more often in opioid compared with control treatment (odds
ratio (OR) 2.76, 95% CI 2.02 to 3.77; 3 trials; 2.4% of participants in opioid
and 0.9% of participants control treatment experienced withdrawal symptoms).
AUTHORS' CONCLUSIONS: The small mean benefit of non-tramadol opioids are
contrasted by significant increases in the risk of adverse events. For the pain
outcome in particular, observed effects were of questionable clinical relevance
since the 95% CI did not include the minimal clinically important difference of
0.37 SMDs, which corresponds to 0.9 cm on a 10-cm VAS
Recommended from our members
Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey.
OBJECTIVE: The objective of the study was to evaluate the impact of rosacea on self-perception, emotional, social, and overall well-being and quality of life in individuals with erythematotelangiectatic rosacea (ETR) and papulopustular rosacea (PPR). DESIGN: We distributed a cross-sectional email invitation for participants in the United States to fill out a web-based survey. PARTICIPANTS: We included adults who reported having previously received a diagnosis of erythematotelangiectatic rosacea or papulopustular rosacea. MEASUREMENTS: Questionnaires measured the psychosocial aspects of rosacea, including the Satisfaction With Appearance Scale and modified Satisfaction With Appearance Scale questionnaires, Impact Assessment for Rosacea Facial Redness, Rosacea-Specific Quality-of-Life questionnaire, and RAND 36-Item Short Form Health Survey. The Impact Assessment for Rosacea Facial Bumps or Pimples was administered to the papulopustular rosacea cohort. RESULTS: Six hundred participants enrolled and completed the survey, with most rating their rosacea as mild or moderate (ETR: 95.6%; PPR: 93.7%). In the erythematotelangiectatic rosacea and papulopustular rosacea cohorts, respectively, 45 and 53 percent disagreed/strongly disagreed that they were satisfied with their appearance due to rosacea; 42 and 27 percent agreed/strongly agreed that they "worry how people will react when they see my rosacea"; and 43 and 59 percent agreed/strongly agreed that they feel their rosacea is unattractive to others. Rosacea-Specific Quality-of-Life total and domain scores indicated negative impact of rosacea for both cohorts. Both cohorts reported worse 36-item Short Form Health Survey overall and domain scores than population norms in the United States. CONCLUSION: Rosacea had wide-ranging, negative effects on self-perceptions and emotional, social, and overall well-being as well as rosacea-specific quality of life. Overall, both erythematotelangiectatic rosacea and papulopustular rosacea cohorts reported a substantial negative impact of rosacea on quality of life on a range of instruments
Prevalence and reasons for smoking in adolescent Swiss childhood cancer survivors.
Smoking harms health, particularly that of childhood cancer survivors, who face risk of pulmonary and cardiovascular diseases because of chemotherapy and radiotherapy to the chest. This nationwide study assessed smoking habits and reasons for smoking in adolescent survivors and healthy peers.
As part of the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to all Swiss resident survivors, who were aged 16-19 years. We compared smoking status and reasons for smoking between 511 survivors, 141 of their siblings, and 1,727 adolescents in a representative population-based study, the Tobacco Monitoring Switzerland (TMS).
Current smoking was less prevalent in survivors (17%) and their siblings (17%) compared with TMS (32%). Survivors and TMS adolescents gave similar reasons for smoking. Stress control, smoking being a habit, and good taste were the reasons for smoking cited most often in both groups. Peer smoking was more important in survivors (49%) than in TMS (34%, P = 0.004). Most important reasons for not smoking in both groups were smoking being unhealthy and not wanting to be addicted.
In Switzerland, survivors smoke as often as their siblings but less than the general population. Peer smoking was a more important reason for smoking in survivors than in the general population, suggesting that reducing smoking in peers could result in a reduction of smoking in survivors. Overall, reasons for smoking were very similar, thus interventions to reduce smoking in survivors could be the same as those used in the general population
Dietary Intake and Diet Quality of Adult Survivors of Childhood Cancer and the General Population: Results from the SCCSS-Nutrition Study.
Childhood cancer survivors (CCSs) are at increased risk of developing chronic health conditions. This may potentially be reduced by a balanced diet. We aimed to compare dietary intake and diet quality using the Alternative Healthy Eating Index (AHEI) of adult CCSs and the general Swiss population. A food frequency questionnaire (FFQ) was completed by CCSs with a median age of 34 (IQR: 29-40) years. We compared dietary intake of 775 CCSs to two population-based cohorts who completed the same FFQ: 1276 CoLaus and 2529 Bus Santé study participants. CCSs consumed particular inadequate amounts of fiber and excessive amounts of sodium and saturated fat. Dietary intake was similar in CCSs and the general population. The mean AHEI was low with 49.8 in CCSs (men: 47.7, women: 51.9), 52.3 in CoLaus (men: 50.2, women: 54.0), and 53.7 in Bus Santé (men: 51.8, women: 54.4) out of a maximum score of 110. The AHEI scores for fish, fruit, vegetables, and alcohol were worse in CCSs than in the general population, whereas the score for sugar-sweetened beverages was better (all p < 0.001). Diet quality at follow-up did not differ between clinical characteristics of CCSs. Long-term CCSs and the general population have poor dietary intake and quality in Switzerland, which suggests similar population-based interventions for everyone